A Phase II Study of Adding the Multikinase Inhibitor Sorafenib (Nexavar) to Existing Endocrine Therapy in Patients With Advanced Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 29 Jan 2015
At a glance
- Drugs Sorafenib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 23 Jan 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 12 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 15 Aug 2013 Planned end date changed from 1 Apr 2013 to 1 Jun 2015 as reported by ClinicalTrials.gov.